• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CVSARRP:一个预测新冠疫苗接种后10855种疾病出现不良至严重不良反应风险的框架。

CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination.

作者信息

Jin Jiahuan, Li Jie

机构信息

Research Center of Bioinformatics, Faculty of Computing, Harbin Institute of Technology, Harbin, Heilongjiang Province, China.

出版信息

Heliyon. 2023 Apr;9(4):e14828. doi: 10.1016/j.heliyon.2023.e14828. Epub 2023 Mar 27.

DOI:10.1016/j.heliyon.2023.e14828
PMID:37009244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10041818/
Abstract

COVID-19 vaccines greatly reduce the risk of infection with SARS-CoV-2. However, some people have adverse reactions after vaccination, and these can sometimes be severe. Gender, age, vaccines, and especially certain diseases histories are related to severe adverse reactions following COVID-19 vaccination. However, there are thousands of diseases and only some are known to be related to these severe adverse reactions. The risk of severe adverse reactions with other diseases remains unknown. Therefore, there is a need for predictive studies to provide improved medical care and minimize risk. Herein, we analyzed the statistical results of existing COVID-19 vaccine adverse reaction data and proposed a COVID-19 vaccine severe adverse reaction risk prediction method, named CVSARRP. The performance of the CVSARRP method was tested using the leave-one-out cross-validation approach. The correlation coefficient between the predicted and real risk is greater than 0.86. The CVSARRP method predicts the risk from adverse reactions to severe adverse reactions after COVID-19 vaccination for 10855 diseases. People with certain diseases, such as central nervous system diseases, heart diseases, urinary system disease, anemia, cancer, and respiratory tract disease, among others, may potentially have increased of severe adverse reactions following vaccination against COVID-19 and experiencing adverse events.

摘要

新冠病毒疫苗能大幅降低感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的风险。然而,有些人在接种疫苗后会出现不良反应,有时这些反应会很严重。性别、年龄、疫苗,尤其是某些疾病史与新冠病毒疫苗接种后的严重不良反应有关。然而,疾病有成千上万种,只有一部分已知与这些严重不良反应有关。其他疾病引发严重不良反应的风险仍然未知。因此,需要进行预测性研究,以提供更好的医疗护理并将风险降至最低。在此,我们分析了现有新冠病毒疫苗不良反应数据的统计结果,并提出了一种新冠病毒疫苗严重不良反应风险预测方法,名为CVSARRP。使用留一法交叉验证方法对CVSARRP方法的性能进行了测试。预测风险与实际风险之间的相关系数大于0.86。CVSARRP方法针对10855种疾病预测了新冠病毒疫苗接种后从不良反应到严重不良反应的风险。患有某些疾病的人,如中枢神经系统疾病、心脏病、泌尿系统疾病、贫血、癌症和呼吸道疾病等,在接种新冠病毒疫苗后可能会有更高的严重不良反应风险并经历不良事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/6cccd9eec5e7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/d3a92e0cd0bb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/b27d8b259401/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/6f6cdfd5e64e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/6cccd9eec5e7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/d3a92e0cd0bb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/b27d8b259401/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/6f6cdfd5e64e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff16/10070089/6cccd9eec5e7/gr4.jpg

相似文献

1
CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination.CVSARRP:一个预测新冠疫苗接种后10855种疾病出现不良至严重不良反应风险的框架。
Heliyon. 2023 Apr;9(4):e14828. doi: 10.1016/j.heliyon.2023.e14828. Epub 2023 Mar 27.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.SARS-CoV-2 疫苗接种对炎症性肠病活动和疫苗相关不良事件发展的影响:来自 PREVENT-COVID 的结果。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1497-1505. doi: 10.1093/ibd/izab302.
4
Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.美国成年人中,既往感染 SARS-CoV-2 与 mRNA COVID-19 疫苗接种后严重全身不良事件的相关性。
Vaccine. 2022 Dec 12;40(52):7653-7659. doi: 10.1016/j.vaccine.2022.10.073. Epub 2022 Nov 1.
5
Smallpox vaccination and adverse reactions. Guidance for clinicians.天花疫苗接种与不良反应。临床医生指南。
MMWR Recomm Rep. 2003 Feb 21;52(RR-4):1-28.
6
Anaphylaxis is a rare reaction in COVID-19 vaccination.在 COVID-19 疫苗接种中,过敏反应较为罕见。
J Biol Regul Homeost Agents. 2021 May-Jun;35(3):839-842. doi: 10.23812/BELLOMO_EDIT_3_21.
7
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.在欧洲和拉丁美洲的十个国家评估 CVnCoV SARS-CoV-2 mRNA 疫苗候选物的疗效和安全性(HERALD):一项随机、观察者设盲、安慰剂对照、2b/3 期临床试验。
Lancet Infect Dis. 2022 Mar;22(3):329-340. doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23.
8
Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.有过敏史的医务人员对 BNT162b2 mRNA COVID-19 疫苗的不良反应。
Respir Investig. 2022 Mar;60(2):248-255. doi: 10.1016/j.resinv.2021.11.007. Epub 2021 Dec 7.
9
Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.辉瑞-生物科技 COVID-19 疫苗在医护人员中接种第一针和第二针后的不良反应。
J Infect Chemother. 2022 Jul;28(7):934-942. doi: 10.1016/j.jiac.2022.03.015. Epub 2022 Mar 25.
10
Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.75 岁及以上成年人接种 BNT162b2 新冠疫苗后的安全性监测。
J Korean Med Sci. 2021 Nov 22;36(45):e318. doi: 10.3346/jkms.2021.36.e318.

本文引用的文献

1
Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases.新型冠状病毒疫苗接种后的心肌炎:发病机制、临床表现、诊断、病理生理学、治疗和结局。该临床共识文件由欧洲心脏病学会心力衰竭协会(ESC)和 ESC 心肌和心包疾病工作组支持。
Eur J Heart Fail. 2022 Nov;24(11):2000-2018. doi: 10.1002/ejhf.2669. Epub 2022 Oct 6.
2
Axillary Lymph Node Swelling Mimicking Breast Cancer Metastasis After COVID-19 Vaccination: A Japanese Case Report and Literature Review.接种 COVID-19 疫苗后腋窝淋巴结肿胀类似乳腺癌转移:日本病例报告及文献复习。
In Vivo. 2022 Mar-Apr;36(2):1041-1046. doi: 10.21873/invivo.12800.
3
Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.分析接种 COVID-19 疫苗的类型和不良反应。
JAMA Netw Open. 2021 Dec 1;4(12):e2140364. doi: 10.1001/jamanetworkopen.2021.40364.
4
COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT.COVID-19 疫苗相关的腋窝和颈部淋巴结病在患有当前或既往乳腺癌和其他恶性肿瘤的患者中:MRI、CT 和 PET-CT 的横断面成像表现。
Korean J Radiol. 2021 Dec;22(12):1938-1945. doi: 10.3348/kjr.2021.0350. Epub 2021 Oct 26.
5
Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study.六种 COVID-19 疫苗在自身免疫性风湿病患者中的不良事件:一项横断面研究。
Rheumatol Int. 2021 Dec;41(12):2105-2108. doi: 10.1007/s00296-021-05017-9. Epub 2021 Oct 7.
6
Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: A case report and review of literature.接种新冠疫苗后出现的罕见不良事件——风湿性多肌痛:一例病例报告及文献综述
Aging Med (Milton). 2021 Aug 15;4(3):234-238. doi: 10.1002/agm2.12171. eCollection 2021 Sep.
7
A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS-CoV-2 vaccine.一例接种第一剂新冠病毒疫苗后发生的严重自身免疫性溶血性贫血病例。
Int J Lab Hematol. 2022 Feb;44(1):e10-e12. doi: 10.1111/ijlh.13653. Epub 2021 Jul 31.
8
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.新型冠状病毒疫苗 NVX-CoV2373 的安全性和有效性。
N Engl J Med. 2021 Sep 23;385(13):1172-1183. doi: 10.1056/NEJMoa2107659. Epub 2021 Jun 30.
9
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.接受 BNT162b2 疫苗接种后结直肠癌患者出现细胞因子释放综合征。
Nat Med. 2021 Aug;27(8):1362-1366. doi: 10.1038/s41591-021-01387-6. Epub 2021 May 26.
10
Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).急性横贯性脊髓炎(ATM):43例新冠病毒相关急性横贯性脊髓炎患者及3例接种ChAdOx1 nCoV-19疫苗(AZD1222)后发生的急性横贯性脊髓炎严重不良事件的临床回顾
Front Immunol. 2021 Apr 26;12:653786. doi: 10.3389/fimmu.2021.653786. eCollection 2021.